Christopher Lademacher

3.3k total citations · 1 hit paper
35 papers, 2.3k citations indexed

About

Christopher Lademacher is a scholar working on Infectious Diseases, Epidemiology and Surgery. According to data from OpenAlex, Christopher Lademacher has authored 35 papers receiving a total of 2.3k indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Infectious Diseases, 15 papers in Epidemiology and 6 papers in Surgery. Recurrent topics in Christopher Lademacher's work include Antifungal resistance and susceptibility (16 papers), Pneumocystis jirovecii pneumonia detection and treatment (7 papers) and Fungal Infections and Studies (6 papers). Christopher Lademacher is often cited by papers focused on Antifungal resistance and susceptibility (16 papers), Pneumocystis jirovecii pneumonia detection and treatment (7 papers) and Fungal Infections and Studies (6 papers). Christopher Lademacher collaborates with scholars based in United States, United Kingdom and Japan. Christopher Lademacher's co-authors include Michael A. Becker, H. Ralph Schumacher, Patricia MacDonald, Eric Lloyd, Barbara Hunt, Nancy Joseph‐Ridge, Robert L. Wortmann, Luis R. Espinoza, Alvin F. Wells and Amit Desai and has published in prestigious journals such as Gastroenterology, The Journal of Clinical Endocrinology & Metabolism and Clinical Infectious Diseases.

In The Last Decade

Christopher Lademacher

35 papers receiving 2.2k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: A 28‐week, phase III, randomized, double‐blind, parallel‐group trial

2008 482 citations H. Ralph Schumacher, Michael A. Becker et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Christopher Lademacher United States	23	1.3k	924	645	618	593	35	2.3k
Barbara Hunt United States	27	1.7k 1.4×	1.6k 1.7×	53 0.1×	197 0.3×	743 1.3×	68	3.0k
Mohamed G. Atta United States	32	994 0.8×	327 0.4×	1.3k 2.0×	545 0.9×	186 0.3×	119	3.1k
Olivier Toupance France	28	487 0.4×	729 0.8×	308 0.5×	623 1.0×	57 0.1×	74	2.8k
Mark Bloch Australia	17	192 0.2×	180 0.2×	669 1.0×	351 0.6×	195 0.3×	40	1.5k
W Amend United States	31	764 0.6×	871 0.9×	64 0.1×	691 1.1×	285 0.5×	87	3.2k
Michel Mourad Belgium	33	219 0.2×	1.3k 1.4×	470 0.7×	262 0.4×	47 0.1×	130	3.7k
Ingeborg A. Hauser Germany	25	214 0.2×	380 0.4×	215 0.3×	540 0.9×	100 0.2×	61	2.2k
Samuel H. Sigal United States	25	201 0.2×	1.4k 1.5×	311 0.5×	2.4k 3.9×	114 0.2×	80	4.2k
James Yun United States	25	154 0.1×	763 0.8×	98 0.2×	414 0.7×	384 0.6×	166	2.5k
C.C. Chu Taiwan	9	160 0.1×	113 0.1×	287 0.4×	186 0.3×	500 0.8×	15	1.5k

Countries citing papers authored by Christopher Lademacher

Since Specialization

Citations

This map shows the geographic impact of Christopher Lademacher's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christopher Lademacher with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christopher Lademacher more than expected).

Fields of papers citing papers by Christopher Lademacher

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Christopher Lademacher. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christopher Lademacher. The network helps show where Christopher Lademacher may publish in the future.

Co-authorship network of co-authors of Christopher Lademacher

This figure shows the co-authorship network connecting the top 25 collaborators of Christopher Lademacher. A scholar is included among the top collaborators of Christopher Lademacher based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Christopher Lademacher. Christopher Lademacher is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Persu, C., et al.. (2021). Efficacy and safety of mirabegron in children and adolescents with neurogenic detrusor overactivity: An open‐label, phase 3, dose‐titration study. Neurourology and Urodynamics. 40(6). 1490–1499. 19 indexed citations

Santoro, Nanette, Arthur Waldbaum, Samuel Lederman, et al.. (2020). Effect of the neurokinin 3 receptor antagonist fezolinetant on patient-reported outcomes in postmenopausal women with vasomotor symptoms: results of a randomized, placebo-controlled, double-blind, dose-ranging study (VESTA). Menopause The Journal of The North American Menopause Society. 27(12). 1350–1356. 44 indexed citations

Takeuchi, Tsutomu, Yoshiya Tanaka, Yuichiro Kaneko, et al.. (2020). ASP5094, a humanized monoclonal antibody against integrin alpha-9, did not show efficacy in patients with rheumatoid arthritis refractory to methotrexate: results from a phase 2a, randomized, double-blind, placebo-controlled trial. Arthritis Research & Therapy. 22(1). 252–252. 11 indexed citations

Andes, David R., Mahmoud A. Ghannoum, Pranab K. Mukherjee, et al.. (2018). Outcomes by MIC Values for Patients Treated with Isavuconazole or Voriconazole for Invasive Aspergillosis in the Phase 3 SECURE and VITAL Trials. Antimicrobial Agents and Chemotherapy. 63(1). 20 indexed citations

Perfect, John R., Oliver A. Cornely, M. Heep, et al.. (2018). Isavuconazole treatment for rare fungal diseases and for invasive aspergillosis in patients with renal impairment: Challenges and lessons of the VITAL trial. Mycoses. 61(7). 420–429. 24 indexed citations

Vincenti, Flavio, Klemens Budde, Pierre Merville, et al.. (2018). A randomized, phase 2 study of ASP0113, a DNA-based vaccine, for the prevention of CMV in CMV-seronegative kidney transplant recipients receiving a kidney from a CMV-seropositive donor. American Journal of Transplantation. 18(12). 2945–2954. 46 indexed citations

Benjamin, Daniel K., David Kaufman, William Hope, et al.. (2018). A Phase 3 Study of Micafungin Versus Amphotericin B Deoxycholate in Infants With Invasive Candidiasis. The Pediatric Infectious Disease Journal. 37(10). 992–998. 27 indexed citations

Delgado‐Herrera, Leticia, Kathryn Lasch, Bernhardt Zeiher, et al.. (2017). Evaluation and performance of a newly developed patient-reported outcome instrument for diarrhea-predominant irritable bowel syndrome in a clinical study population. Therapeutic Advances in Gastroenterology. 10(9). 673–687. 4 indexed citations

Keirns, James J., Amit Desai, Donna Kowalski, et al.. (2017). QT Interval Shortening With Isavuconazole:In VitroandIn VivoEffects on Cardiac Repolarization. Clinical Pharmacology & Therapeutics. 101(6). 782–790. 59 indexed citations

10.

Desai, Amit, Laura Kovanda, David R. Andes, et al.. (2016). No Dose Adjustment Necessary for Isavuconazole in Obese Patients. Open Forum Infectious Diseases. 3(suppl_1). 1 indexed citations

11.

Desai, Amit, Takao Yamazaki, Donna Kowalski, et al.. (2016). Pharmacokinetic and Pharmacodynamic Evaluation of the Drug‐Drug Interaction Between Isavuconazole and Warfarin in Healthy Subjects. Clinical Pharmacology in Drug Development. 6(1). 86–92. 22 indexed citations

12.

Yamazaki, Takao, Amit Desai, David Han, et al.. (2016). Pharmacokinetic Interaction Between Isavuconazole and a Fixed‐Dose Combination of Lopinavir 400 mg/Ritonavir 100 mg in Healthy Subjects. Clinical Pharmacology in Drug Development. 6(1). 93–101. 23 indexed citations

13.

Townsend, Robert, Shahzad Akhtar, Donna Kowalski, et al.. (2016). Pharmacokinetic Evaluation of CYP3A4‐Mediated Drug‐Drug Interactions of Isavuconazole With Rifampin, Ketoconazole, Midazolam, and Ethinyl Estradiol/Norethindrone in Healthy Adults. Clinical Pharmacology in Drug Development. 6(1). 44–53. 92 indexed citations

14.

Marquis, Patrick, Kathryn Lasch, Leticia Delgado‐Herrera, et al.. (2014). Qualitative Development of a Patient-Reported Outcome Symptom Measure in Diarrhea-Predominant Irritable Bowel Syndrome. Clinical and Translational Gastroenterology. 5(6). e59–e59. 14 indexed citations

15.

Lasch, Kathryn, Leticia Delgado‐Herrera, Smita Kothari, et al.. (2011). The Irritable Bowel Syndrome-Diarrhea (IBS-D) Daily Symptom Diary and Event Log: A Newly Developed Patient-Reported Outcome (PRO) Measure. Gastroenterology. 140(5). S–612. 2 indexed citations

16.

Grabowski, Brian, Reza Khosravan, Jingtao Wu, Laurent Vernillet, & Christopher Lademacher. (2010). Effect of hydrochlorothiazide on the pharmacokinetics and pharmacodynamics of febuxostat, a non‐purine selective inhibitor of xanthine oxidase. British Journal of Clinical Pharmacology. 70(1). 57–64. 20 indexed citations

17.

Becker, Michael A., H. Ralph Schumacher, Luis R. Espinoza, et al.. (2010). The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. Arthritis Research & Therapy. 12(2). R63–R63. 381 indexed citations

18.

Becker, Michael A., H. Ralph Schumacher, Patricia MacDonald, Eric Lloyd, & Christopher Lademacher. (2009). Clinical Efficacy and Safety of Successful Longterm Urate Lowering with Febuxostat or Allopurinol in Subjects with Gout. The Journal of Rheumatology. 36(6). 1273–1282. 200 indexed citations

19.

Becker, Michael A., Patricia MacDonald, Barbara Hunt, Christopher Lademacher, & Nancy Joseph‐Ridge. (2008). Determinants of the Clinical Outcomes of Gout During the First Year of Urate-Lowering Therapy. Nucleosides Nucleotides & Nucleic Acids. 27(6-7). 585–591. 73 indexed citations

20.

Schumacher, H. Ralph, Michael A. Becker, Elisabeth A. Lloyd, Penny A. MacDonald, & Christopher Lademacher. (2008). Febuxostat in the treatment of gout: 5-yr findings of the FOCUS efficacy and safety study. Lara D. Veeken. 48(2). 188–194. 181 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact